Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System.

Scalable lentiviral vector (LV) manufacturing is vital for successful commercialization of LV-based gene and cell therapy products. Accordingly, efforts are currently focused on developing and adapting technologies to address both upstream and downstream production bottlenecks. To overcome the limitations of current upstream processes, researchers are now favoring the use of bioreactors over traditional two-dimensional culture platforms. Bioreactors provide many advantages for manufacturing biomolecules, including process automation, tight regulation of production conditions, reduced labor input, and higher productivity potential. This study describes a transient LV production strategy employing a single-use, packed-bed bioreactor vessel. Functional LV titers in the 106 TU/mL range were achieved, and after concentration yields of up to 109 TU/mL were attained. This proof of principle study demonstrates that LV can be successfully produced in a packed-bed system. With further optimization, a packed-bed bioreactor could offer a potential scale-out solution for LV manufacturing.

[1]  S. Ylä-Herttuala,et al.  Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor , 2017, Gene Therapy.

[2]  GándaraCarolina,et al.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice. , 2017 .

[3]  Sven Ansorge,et al.  Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines , 2017, Human gene therapy methods.

[4]  M. Donnelley,et al.  Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways , 2017, Experimental lung research.

[5]  R. Whittaker,et al.  A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies , 2017, Human gene therapy methods.

[6]  Mondher Toumi,et al.  Gene therapies development: slow progress and promising prospect , 2017, Journal of market access & health policy.

[7]  Martin Donnelley,et al.  Challenges of up-scaling lentivirus production and processing. , 2016, Journal of biotechnology.

[8]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[9]  Krishnendu Roy,et al.  Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives. , 2016, Annual review of chemical and biomolecular engineering.

[10]  Frederic D Bushman,et al.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.

[11]  A. Galy,et al.  Influence of mildly acidic pH conditions on the production of lentiviral and retroviral vectors. , 2014, Human gene therapy. Clinical development.

[12]  T. Mukhopadhyay,et al.  Characterization of lentiviral vector production using microwell suspension cultures of HEK293T-derived producer cells. , 2013, Human gene therapy methods.

[13]  D. Williams,et al.  Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection , 2011, Gene Therapy.

[14]  L. Naldini,et al.  Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. , 2011, Human gene therapy.

[15]  Y. Durocher,et al.  Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures , 2009, The journal of gene medicine.

[16]  J. Gray,et al.  Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. , 2009, Blood.

[17]  Mohamed Al-Rubeai,et al.  Monitoring pH and dissolved oxygen in mammalian cell culture using optical sensors , 2008, Cytotechnology.

[18]  Y. Durocher,et al.  Production of lentiviral vectors by large‐scale transient transfection of suspension cultures and affinity chromatography purification , 2007, Biotechnology and bioengineering.

[19]  F Meuwly,et al.  Packed-bed bioreactors for mammalian cell culture: bioprocess and biomedical applications. , 2007, Biotechnology advances.

[20]  D. Trono,et al.  Production and Titration of Lentiviral Vectors , 2006, Current protocols in neuroscience.

[21]  F. Meuwly,et al.  Use of glucose consumption rate (GCR) as a tool to monitor and control animal cell production processes in packed-bed bioreactors. , 2006, Journal of biotechnology.

[22]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[23]  K. Cornetta,et al.  Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods , 2002, Gene Therapy.

[24]  M. Fuller,et al.  Helper plasmids for production of HIV-1-derived vectors. , 2001, Human gene therapy.

[25]  P. Cruz,et al.  Comparison of Different Bioreactor Systems for the Production of High Titer Retroviral Vectors , 2001, Biotechnology progress.